Bio-Rad Q3 profit beats estimates helped by cost management

Bio-Rad Laboratories

29/10/2025 20:49

Overview

Bio-Rad Q3 2025 revenue grows 0.5%, beating analyst expectations, per LSEG data

Adjusted EPS for Q3 2025 beats analyst estimates, reflecting effective cost management

Company reports net loss due to fair market value change in Sartorius AG investment

Outlook

Bio-Rad maintains full-year 2025 revenue growth forecast at 0 to 1.0%

Company expects 2025 non-GAAP operating margin of 12.0 to 13.0%

Result Drivers

COST MANAGEMENT - Disciplined cost management contributed to better-than-expected operating margins

FUNDING CHALLENGES - Reduced demand for instruments due to constrained academic research and biotech funding environment

DIABETES TESTING RATES - Lower reimbursement rates for diabetes testing in China impacted Clinical Diagnostics sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$653 mln
$651.80 mln (5 Analysts)
Q3 Adjusted EPS
Beat
$2.26
$1.95 (5 Analysts)
Q3 EPS
-$12.70
Q3 Net Income
-$341.90 mln
Q3 Gross Margin
52.60%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Bio Rad Laboratories Inc is $325.00, about 1.7% below its October 28 closing price of $330.42

The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 27 three months ago

Press Release: ID:nBwc1dpQYa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)